Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 17, Issue 10, Pages 1002-1024Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161211795589337
Keywords
PACAP; VIP; Neuroprotection; Stroke; Traumatic brain injury; G protein-coupled receptor; Bioactive conformation; Peptide drug design
Categories
Funding
- Institut National de la Sante et de la Recherche Medicale [INSERM U982]
- Conseil Regional de Haute-Normandie
- IREB
- TC2N
- ANR
- Canadian Institutes of Health Research (CIHR)
- Institut National de la Recherche Scientifique
- Fonds de la Recherche en Sante du Quebec (FRSQ)
- Heart and Stroke Foundation of Canada
Ask authors/readers for more resources
In neurological insults, such as cerebral ischemia and traumatic brain injury, complex molecular mechanisms involving inflammation and apoptosis are known to cause severe neuronal cell loss, emphasizing the necessity of developing therapeutic strategies targeting simultaneously these two processes. Over the last decade, numerous in vitro and in vivo studies have demonstrated the unique therapeutical potential of pituitary adenylate cyclase-activating polypeptide (PACAP) for the treatment of neuronal disorders involving apoptotic cell death and neuroinflammation. The neuroprotective activity of PACAP is based on its capacity to reduce the production of deleterious cytokines from activated microglia, to stimulate the release of neuroprotective agents from astrocytes and to inhibit proapoptotic intracellular pathways. However, the use of PACAP as a clinically applicable drug is hindered by its peptidic nature. As most natural peptides, native PACAP shows poor metabolic stability, low bioavailability, inadequate distribution and rapid blood clearance. Moreover, injection of PACAP to human can induce peripheral adverse side effects. Therefore, targeted chemical modifications and/or conjugation of PACAP to different macromolecules are required to improve the pharmacokinetic and pharmacological properties of PACAP. This review presents the chemical, biochemical and pharmacological strategies that are currently under development to convert PACAP from a hypophysiotropic neurohormone into a clinically relevant neuroprotective drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available